Why Coya Therapeutics Is A Smart Speculative Buy For Neurodegenerative Diseases [Seeking Alpha]
Coya Therapeutics, Inc. (NASDAQ: COYA) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $14.00 price target on the stock.
Coya Therapeutics Presents Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium [Yahoo! Finance]
Coya Therapeutics Presents Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium
Coya Therapeutics to Participate in the Mizuho Neuroscience Summit